Recent News

• 04.02.2025 - FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 04.02.2025 - FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 04.02.2025 - FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.28.2025 - FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
• 03.28.2025 - FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
• 03.28.2025 - FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
• 03.17.2025 - FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call
• 03.17.2025 - FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call
• 03.17.2025 - FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.17.2025 - FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Recent Filings

• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 8-K Current report
• 03.28.2025 - 8-K Current report
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 8-K Current report
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities